Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients. A multicenter study by EBMT IEWP.
Fekadu-Siebald J, Salzmann-Manrique E, Heusel JR, Willasch A, Hauck F, Gonzalez-Granado LI, Chavoshzadeh Z, Sharafian S, Cuntz F, Baris S, Finocchi A, Algeri M, Sherkat R, Klaudel-Dreszler M, Zeidler C, Bellanné-Chantelot C, Kindle G, Beaupain B, Paillard C, Seidel MG, Bader P, Albert MH, Neven B, Donadieu J, Bakhtiar S. Fekadu-Siebald J, et al. Among authors: salzmann manrique e. Blood Adv. 2025 Jan 7:bloodadvances.2024014344. doi: 10.1182/bloodadvances.2024014344. Online ahead of print. Blood Adv. 2025. PMID: 39775668
Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation.
Kayser S, Salzmann-Manrique E, Serve H, Bader P, Klusmann JH, Seidl C, Schwäble J, Bug G, Ullrich E. Kayser S, et al. Among authors: salzmann manrique e. Front Immunol. 2024 Dec 16;15:1413927. doi: 10.3389/fimmu.2024.1413927. eCollection 2024. Front Immunol. 2024. PMID: 39737173 Free PMC article.
Immune profiling and functional analysis of NK and T cells in ataxia telangiectasia.
Graafen L, Heinze A, Albinger N, Salzmann-Manrique E, Ganß F, Hünecke S, Cappel C, Wölke S, Donath H, Trischler J, Theilen TM, Heller C, Königs C, Ehl S, Bader P, Klingebiel T, Klusmann JH, Zielen S, Schubert R, Ullrich E. Graafen L, et al. Among authors: salzmann manrique e. Front Immunol. 2024 Aug 6;15:1377955. doi: 10.3389/fimmu.2024.1377955. eCollection 2024. Front Immunol. 2024. PMID: 39165363 Free PMC article.
Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.
Heim C, Hartig L, Weinelt N, Moser LM, Salzmann-Manrique E, Merker M, Wels WS, Tonn T, Bader P, Klusmann JH, van Wijk SJL, Rettinger E. Heim C, et al. Among authors: salzmann manrique e. Mol Ther Oncol. 2024 Apr 11;32(2):200802. doi: 10.1016/j.omton.2024.200802. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38706988 Free PMC article.
Look at the future -perceptions of fertility counseling and decision-making among adolescents and their parents in the context of hematopoietic stem cell transplantation-experience of one major center for pediatric stem cell transplantation.
Barnbrock A, Hamannt F, Salzmann-Manrique E, Rohm T, Lange S, Bader P, Jarisch A. Barnbrock A, et al. Among authors: salzmann manrique e. Front Pediatr. 2023 Nov 29;11:1249558. doi: 10.3389/fped.2023.1249558. eCollection 2023. Front Pediatr. 2023. PMID: 38094191 Free PMC article.
Pediatric Patients with Stage IV Rhabdomyosarcoma Significantly Benefit from Long-Term Maintenance Therapy: Results of the CWS-IV 2002 and the CWS DOK IV 2004-Trials.
Tramsen L, Bochennek K, Sparber-Sauer M, Salzmann-Manrique E, Scheer M, Dantonello T, Borkhardt A, Dirksen U, Thorwarth A, Greiner J, Ebinger M, Weclawek-Tompol J, Ladenstein R, Ljungman G, Hallmen E, Lehrnbecher T, Koscielniak E, Klingebiel T. Tramsen L, et al. Among authors: salzmann manrique e. Cancers (Basel). 2023 Mar 30;15(7):2050. doi: 10.3390/cancers15072050. Cancers (Basel). 2023. PMID: 37046711 Free PMC article.
Donor-type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors.
Jarisch A, Salzmann-Manrique E, Soerensen J, Sach G, Rettinger E, Willasch A, Bakhtiar S, Klarmann D, Bräuninger S, Moser L, Fekadu J, Hutter M, Klingebiel T, Klusmann JH, Bader P, Bonig H. Jarisch A, et al. Among authors: salzmann manrique e. Br J Haematol. 2023 Jun;201(6):1159-1168. doi: 10.1111/bjh.18761. Epub 2023 Mar 22. Br J Haematol. 2023. PMID: 36949601
44 results